​
​

Celldex Therapeutics Ownership | Who Owns Celldex Therapeutics?

OverviewForecastRevenueFinancialsChart

Celldex Therapeutics Ownership Summary

Celldex Therapeutics is owned by 118.22% institutional investors, 0.30% insiders. Wellington management group llp is the largest institutional shareholder, holding 13.72% of CLDX shares. Vanguard Health Care Inv is the top mutual fund, with 6.85% of its assets in Celldex Therapeutics shares.

CLDX Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockCelldex Therapeutics118.22%0.30%-18.52%
SectorHealthcare Stocks 47.38%7.99%44.63%
IndustryBiotech Stocks 45.43%7.81%46.75%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Wellington management group llp8.08M13.72%$298.89M
Fmr7.83M13.30%$289.76M
Blackrock4.69M7.97%$173.61M
Vanguard group3.74M6.35%$138.38M
Kynam capital management, lp3.39M5.76%$125.43M
Eventide asset management3.33M5.65%$123.14M
Price t rowe associates inc /md/3.17M5.39%$117.41M
Polar capital3.08M5.23%$113.87M
Bellevue group2.97M5.05%$109.98M
State street2.66M4.52%$98.41M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Kynam capital management, lp3.39M9.67%$125.43M
5am venture management497.27K4.12%$18.40M
Commodore capital lp1.43M3.60%$52.74M
Silverarc capital management374.91K3.27%$13.88M
Tsp capital management group249.22K2.89%$9.22M
Eventide asset management3.33M2.11%$123.14M
Affinity asset advisors475.40K2.03%$17.59M
Bellevue group2.97M1.79%$109.98M
Redmile group718.72K1.61%$26.60M
Eversept partners, lp633.01K1.60%$23.43M

Top Buyers

HolderShares% AssetsChange
Novo850.00K1.58%850.00K
Point72 asset management1.94M0.19%654.19K
Commodore capital lp1.43M3.60%558.53K
Kynam capital management, lp3.39M9.67%488.97K
Marshall wace, llp1.38M0.07%479.07K

Top Sellers

HolderShares% AssetsChange
Fmr7.83M0.02%-1.90M
Logos global management lp---650.00K
Sofinnova investments---547.71K
State street2.66M0.00%-320.66K
Candriam s.c.a.---317.51K

New Positions

HolderShares% AssetsChangeValue
Novo850.00K1.58%850.00K$31.46M
Panagora asset management118.35K0.02%118.35K$4.38M
Artia global partners lp75.30K0.54%75.30K$2.79M
Capital fund management44.45K0.00%44.45K$1.64M
Mirae asset global etfs35.41K0.00%35.41K$1.31M

Sold Out

HolderChange
Scarborough advisors-6.00
Nelson, van denburg & campbell wealth management group-10.00
Householder group estate & retirement specialist-11.00
Innealta capital-17.00
Hartford financial management-18.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 2024187-8.33%69,597,4190.41%1180.85%104-18.75%4811.63%
Mar 31, 202420415.25%69,309,91913.65%1170.86%12840.66%43-10.42%
Dec 31, 202317712.03%60,984,74520.59%1171.02%9115.19%4814.29%
Sep 30, 2023158-1.86%50,572,7510.41%1070.94%791.28%42-8.70%
Jun 30, 2023161-4.73%50,368,6831.75%1060.97%782.63%46-14.81%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Vanguard Health Care Inv4.54M6.85%1.17M
BB Biotech AG Ord3.07M4.63%100.00K
Vanguard Total Stock Mkt Idx Inv2.07M3.12%2.12K
Eventide Gilead N1.76M2.65%206.37K
iShares Russell 2000 ETF1.66M2.50%-3.74K
Eventide Healthcare & Life Sciences I1.56M2.35%-
Polar Capital Biotech S Inc1.25M1.89%-500.00K
Polar Capital Healthcare Opports Inc1.15M1.73%-
Vanguard Explorer Inv1.13M1.71%-
T. Rowe Price New Horizons1.05M1.59%-3.31K

Recent Insider Transactions

DateNameRoleActivityValue
Nov 11, 2024Marucci Anthony S PRESIDENT & CEOBuy$308.43K
Jun 14, 2024Martin Samuel Bates SVP AND CFOSell$608.31K
Jun 14, 2024Crowley Elizabeth SR. VP & CPDOSell$1.05M
Jun 07, 2024Crowley Elizabeth SR. VP & CPDOSell$525.87K
Jun 07, 2024Young Diane C. SVP, CHIEF MEDICAL OFFICERSell$1.59M

Insider Transactions Trends

DateBuySell
2024 Q41-
2024 Q2-12
2024 Q1--
2023 Q2--
2023 Q1--

CLDX Ownership FAQ

Who Owns Celldex Therapeutics?

Celldex Therapeutics shareholders are primarily institutional investors at 118.22%, followed by 0.30% insiders and -18.52% retail investors. The average institutional ownership in Celldex Therapeutics's industry, Biotech Stocks , is 45.43%, which Celldex Therapeutics exceeds.

Who owns the most shares of Celldex Therapeutics?

Celldex Therapeutics’s largest shareholders are Wellington management group llp (8.08M shares, 13.72%), Fmr (7.83M shares, 13.30%), and Blackrock (4.69M shares, 7.97%). Together, they hold 34.98% of Celldex Therapeutics’s total shares outstanding.

Does Blackrock own Celldex Therapeutics?

Yes, BlackRock owns 7.97% of Celldex Therapeutics, totaling 4.69M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 173.61M$. In the last quarter, BlackRock increased its holdings by 178.84K shares, a 3.96% change.

Who is Celldex Therapeutics’s biggest shareholder by percentage of total assets invested?

Kynam capital management, lp is Celldex Therapeutics’s biggest shareholder by percentage of total assets invested, with 9.67% of its assets in 3.39M Celldex Therapeutics shares, valued at 125.43M$.

Who is the top mutual fund holder of Celldex Therapeutics shares?

Vanguard Health Care Inv is the top mutual fund holder of Celldex Therapeutics shares, with 6.85% of its total shares outstanding invested in 4.54M Celldex Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools